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ABSTRACT
The Japanese Guideline for the Diagnosis and Treatment of Allergic Diseases 2010 (JAGL 2010) describes
childhood asthma based on the Japanese Pediatric Guideline for the Treatment and Management of Asthma
2008 (JPGL 2008) published by the Japanese Society of Pediatric Allergy and Clinical Immunology. JAGL 2010
provides information on diagnosis by age groups from infancy to puberty, treatment for acute exacerbations,
long-term management by medication, daily life guidance, and patient education to allow physicians, not spe-
cialized in childhood asthma, to refer to this guideline for routine medical treatment.
JAGL differs from the Global Initiative for Asthma Guideline (GINA) in that the former emphasizes long-term
management of childhood asthma based on asthma severity and early diagnosis and intervention at <2 years
and 2-5 years of age. However, a management method, including step-up or step-down of long-term manage-
ment agents based on the status of asthma symptoms, is easy to understand and thus JAGL is suitable for rou-
tine medical treatment. JAGL also introduced treatment and management using a control test for children, rec-
ommending treatment and management aimed at complete control through avoiding exacerbation factors and
appropriate use of antiinflammatory agents.
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1. DEFINITION AND PATHOPHYSIOLOGY
OF CHILDHOOD ASTHMA
Childhood asthma causes repeated dyspnea accom-
panied by paroxysmal whistlingwheezing. The dysp-
nea is spontaneously or therapeutically remitted or
cured and rarely lethal. Like adult asthma, childhood
asthma is characterized by chronic airway inflamma-
tion1,2 and airway remodeling.3-7
Asthma is chronic airway inflammation caused by
the activation of eosinophils, mast cells, lymphocytes,
etc., and airway mucosal damage. The view that
asthma is a condition of chronic inflammation has im-
portant implications for asthma treatment and man-
agement, being fundamental to understanding the
need for antiinflammatory agents for basic treatment
of persistent asthma. Remodeling, which may influ-
ence the prognosis of asthma, is unknown in many
aspects, such as causes, onset time, and effects of an-
tiinflammatory treatment.
Airway hyperresponsiveness, which is characteris-
tic of asthma, is promoted by airway epithelial dam-
age caused by airway inflammation. It can be as-
sessed based on reactions to inhaled histamine, ace-
tylcholine, etc. Exercise induced asthma is also con-
sidered a phenomenon associated with airway hyper-
responsiveness.
2. DIAGNOSIS AND DIFFERENTIAL DIAG-
NOSIS OF CHILDHOOD ASTHMA
The typical symptom of asthma attack is dyspnea ac-
companied by whistlingwheezing. Expiratory dysp-
nea occurs mainly during an asthma attack. However,
as symptoms progress, inspiratory dyspnea may co-
exist. If such symptoms are repeated, it is relatively
easy to diagnose symptomatic asthma. However,
some patients present with misleading symptoms. Ta-
ble 1 summarizes the physiological and immunologi-
cal examinations and allergy tests, which may aid in
increasing the accuracy of diagnosis.
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Table　1　Reference criteria for asthma diagnosis
1. Respiratory functions: spirogram, fl ow volume curve, peak expiratory fl ow (PEF) rate, and reactivity and reversibility for β2
stimulants
2. Airway hyperresponsiveness test: acetylcholine, methacholine, and histamine thresholds and exercise stress test
3. Data indicating airway infl ammation: eosinophils in rhinorrhea and sputum, mast cells (basophils), and fraction of exhaled ni-
tric oxide (FeNO)
4. IgE: total serum IgE level, specifi c IgE antibody, immediate skin response, and antigen inhalation test
5. Family and past histories of allergic diseases
Table　2　Findings for infantile asthma diagnosis
- At least one of parents is diagnosed with bronchial asthma by a physician (including past history).
- Specifi c IgE antibody for inhalation antigen is detected in at least one of parents.
- Diseased child is diagnosed with atopic dermatitis by a physician (including past history).
- Specifi c IgE antibody for inhalation antigen is detected in diseased child.
- High serum IgE level in diseased child or his/her family (serum IgE level should be determined by considering age).
- Eosinophils and creola bodies found in sputum (examine nasal discharge eosinophilia and peripheral blood eosinophilia).
- Expiratory wheezing occurs when there is no airway infection.
- Expiratory wheezing and labored respiration or oxygen saturation are improved after β2 stimulant inhalation.
2.1. DIAGNOSIS OF INFANTILE ASTHMA
In this textbook, infantile asthma is defined as asthma
affecting infants aged <2 years. It is difficult to define
the criteria of infantile asthma. However, for early in-
tervention, a diagnosis of infantile asthma can be
made if there are 3 or more episodes of marked expi-
ratory wheezing, regardless of the presence of respi-
ratory tract infection. These criteria may include
wheezing caused by viral infection, etc. Table 2 lists
findings for infantile asthma for more accurate diag-
nosis.
2.2. DIFFERENTIAL DIAGNOSIS
Table 3 shows differential diagnosis of wheezing in
children. If wheezing occurs first, differential diagno-
sis should be made for children with wheezing symp-
toms, particularly with acute wheezing. In infants,
even the accumulation of secretion in the lower respi-
ratory tract, resulting from bronchitis, pneumonia,
etc., may cause repeated wheezing, thus requiring a
differential diagnosis. Recurrent wheezing is easily
diagnosed in children with underlying diseases, such
as history of respiratory disorder and congenital
heart disease during infancy. However, caution
should be exercised for airway stenosis caused by a
vascular ring, etc., and wheezing caused by gastroe-
sophageal reflux disease.
2.3. COUGH VARIANT ASTHMA AND TYPICAL
ASTHMA
Cough variant asthma (CVA)8-10 differs from typical
asthma in that the former presents with prolonged
cough and exacerbation of airway hyperresponsive-
ness, but lacks wheezing. Inhaled β2 stimulants are
effective for cough in CVA. CVA presents with airway
inflammation; however, CVA is milder than asthma
and has a higher threshold for wheezing than for air-
way constriction and a lower rate of airway constric-
tion to stimuli. The underlying mechanism of pro-
longed cough is unknown. Reportedly, half of patients
with CVA develop asthma during the course.
3. EPIDEMIOLOGY OF CHILDHOOD AS-
THMA
3.1. PREVALENCE
Three nationwide surveys have been conducted in
Japan, i.e., American Thoracic Society Division of
Lung Diseases (ATS-DLD),11,12 International Study of
Asthma and Allergies in Childhood (ISAAC),13,14 and
a school health survey. The prevalence of asthma is
characterized by (i) being more common among juve-
niles, particularly male children, more particularly
male infants; (ii) varying 2-fold or more among re-
gions; and (iii) having increased 2-fold in Japan in the
past 20 years.
3.2. COMPLICATIONS (Table 4)
Allergic rhinitis, allergic conjunctivitis, and atopic
dermatitis are common as coexisting allergic dis-
eases caused by the same mechanism as asthma. Of
note, the complication rate of allergic rhinitis is
50%.
3.3. PROGNOSIS
The remission rate is lower in cases that are more se-
rious. Remission is defined as an asymptomatic status
Childhood Asthma
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Table　3　Differential diagnosis of wheezing in children
Acute wheezing Recurrent wheezing
Infants (<2 years old)
Acute bronchiolitis
Bronchitis and pneumonia
Anaphylaxis caused by food allergy, etc.
Croup
Foreign body in airway
Infantile asthma
Laryngomalacia and tracheomalacia
Chronic lung disease (after respiratory disorder dur-
ing the newborn period)
Airway stenosis caused by congenital disorder 
(vascular ring, etc.)
Gastroesophageal refl ux disease
Aspiration
Bronchiolitis obliterans
Heart failure
Infants (2-5 years old)
Foreign body in airway
Anaphylaxis caused by food allergy, etc.
Croup
Airway compressed by tumor (mediastinal tu-
mor, etc.)
Asthma
Chronic lung disease (after respiratory disorder dur-
ing the newborn period)
Bronchiectasis
Gastroesophageal refl ux disease
Bronchiolitis obliterans
Congenital immunodefi ciency disease (recurrent 
respiratory tract infection)
School age or older
Bronchitis
Pneumonia
Pulmonary tuberculosis
Pulmonary embolism and pulmonary edema
Airway compressed by tumor (mediastinal tu-
mor, etc.)
Foreign body in airway
Asthma
Vocal cord dysfunction
Psychogenic cough
Rhinitis and sinusitis
Hypersensitivity pneumonitis
Allergic broncho pulmonary aspergillosis
Sarcoidosis
Table　4　Frequency of allergy complications in children with bronchial asthma
Allergy complications
Names of allergic diseases
Bronchial asthma Atopic dermatitis
Allergic 
rhinitis
Allergic 
conjunctivitis Pollinosis
Bronchial asthma (%) ― 14.6 16.9 16.3 14.2
Atopic dermatitis (%) 30.9 ― 26.2 27.6 27.3
Allergic rhinitis (%) 52.8 38.8 ― 64.1 87.8
Allergic conjunctivitis (%) 24.4 19.5 30.6 ― 72.2
Pollinosis (%) 12.5 11.3 24.6 42.3 ―
Survey in elementary school students in western Japan in 2002.
without any treatment, and is thus differentiated from
cure. A remission status that continues for 5 years or
longer is considered a clinical cure. Furthermore, if
respiratory function and airway hyperresponsiveness
recover to normal levels, the status is determined as a
functional cure.
3.4. DEATH FROM ASTHMA (Fig. 1)
The number of deaths from asthma during childhood
has markedly decreased. Some characteristics can be
noted: (i) mortality in patients with asthma, aged 5-34
years, has decreased to 0.1 per 100,000 population;
(ii) mortality in those aged 0-4 years is higher than
that in older children; (iii) mortality in those aged 15-
19 years decreases and is more common among
males and unstable; (iv) suffocation is the leading
cause of death; (v) most deaths result from severe
symptoms, but some moderate or mild symptoms
may also result in death15; (vi) unexpected sudden
exacerbation and delayed appropriate consultation
are common as causes of death from asthma; and
(vii) misjudgment of seizure severity and excessive
dependence on pressurized metered dose inhalers
(pMDI) of short-acting β2 agonists are other causes
of death.16
Nishimuta T et al.
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Fig.　1　Mortality from asthma in children of 5-19 years old from 1980 to 2009.
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3.5. PREVENTION OF AND MEASURES AGAIN-
ST DEATH FROM ASTHMA
To reduce deaths from asthma, early diagnosis and
treatment and patient education should be thor-
oughly conducted. Instructions for appropriate use of
short-acting β2 agonist pMDI, measures against
acute seizures, thorough antiinflammatory therapy
with inhaled corticosteroids, compliance, etc., are
particularly important.
4. MEASURES AGAINST ACUTE SEIZURES
IN CHILDHOOD ASTHMA
4.1. ASSESSMENT OF SEIZURE INTENSITY
Seizure intensity is classified into 4 stages, i.e., minor,
moderate, and major seizures and respiratory insuffi-
ciency, based on the degree of impairment of respira-
tory status and living conditions (Table 5). Since in-
fants cannot recognize dyspnea, seizure intensity is
determined based on objective findings. Ill-temper,
vomiting, screaming, and difficulty sleeping unless
held by mother are important interview items for se-
vere seizure (Table 6).
The criteria of seizure intensity are determined by
measuring oxygen saturation (SpO2) using a pulse
oximeter and peak expiratory flow (PEF) using a PEF
meter. However, since SpO2 widely varies among in-
fants compared with schoolchildren, caution should
be exercised in evaluating seizure intensity in infants.
4.2. TREATMENT AND PROCEDURES IN OUT-
PATIENT DEPARTMENTS (Fig. 2)
4.2.1. Initial Treatment
(1) Treatment of minor seizure: Administer an in-
haled β2 stimulant (salbutamol or procaterol) using a
nebulizer. Use 0.1-0.3 mL for infants and 0.2-0.4 mL
for school children or older adolescents, diluted in
physiological saline (2 ml) or DSCG inhalant solution
(1 ampule = 2 mL).
(2) Treatment of moderate seizures: Administer an
inhaled β2 stimulant using a nebulizer. Consider oxy-
gen inhalation for patients with <95% SpO2. For pa-
tients with insufficient response, perform inhalation
again 20-30 min later. Inhalation can be repeated
three times. If ineffective, consider additional treat-
ment.
(3) Treatment of major seizures and respiratory in-
sufficiency: Administer an inhaled β2 stimulant with a
nebulizer, while performing oxygenation. After secur-
ing vascular access, start initial transfusion and intra-
venous steroid administration. Intravenous infusion
of aminophylline can also be added for children aged
2 years. Consider its indications before use (Table
7). It is recommended that specialists use this treat-
ment for children aged <2 years.
4.2.2. Determination of Efficacy and Measures
(Fig. 2)
The efficacy of initial treatment is determined based
on changes in seizure intensity. Classify the efficacy
into favorable response, insufficient response, no re-
sponse, and exacerbation based on the changes.
(1) Minor seizure
(i) Favorable response: After β2 stimulant inhala-
tion for 15-30 min, cough and wheezing almost disap-
pear and SpO2 becomes 97%. The peak expiratory
flow rates among school children or older adoles-
cents are predicted values or80% of the best value.
If in this status, the patient can go home. (ii) Insuffi-
cient response: Mild cough and wheezing remain
even after β2 stimulant inhalation. Administer an in-
haled β2 stimulant again 20-30 min later. (iii) No re-
sponse or exacerbation: If β2 stimulant inhalation
causes no response or exacerbates symptoms, con-
duct an additional treatment equivalent to that for
moderate seizure.
(2) Moderate seizure
Childhood Asthma
Allergology International Vol 60, No2, 2011 www.jsaweb.jp 151
Table　5　Criteria for seizure intensity
Minor seizures Moderate seizures Major seizures
Respiratory 
insufficiency
Respiration status Wheezing Mild Apparent Marked Reduced or 
eliminated
Retractive breathing None - mild Apparent Marked Marked
Prolonged expiration - + Apparent† Marked
Orthopnea Can lie down Like sitting 
position
Bend forward
Cyanosis - - Possible +
Respiratory rate Slightly increased Increased Increased Undetermined
Normal respiratory rate in children when awaking <2 months <60/min
2-12 months <50/min
1-5 years old <40/min
6-8 years old <30/min
Feeling of dyspnea During rest - + Marked Marked
During walking (+) when in a 
hurry
Marked during 
walking
Difficulty in 
walking
Abasia
Daily life Speech Pause after one 
sentence
Pause after 
phrases
Pause after 
one word
Impossible
Diet Almost normal Slightly difficult Difficult Impossible
Sleep Can sleep Occasionally 
wake up
Disturbed Disturbed
Impaired consciousness Excitation Normal Slightly excited Excited Confused
Lowering of consciousness - - Slightly lowered +
PEF  (before inhalation) >60% 30-60% <30% Unmeasurable
 (after inhalation) >80% 50-80% <50% Unmeasurable
SpO2 (atmosphere) ≥96% 92-95% ≤91% <91
PaCO2 <41 mmHg <41 mmHg <41-60 mmHg >60 mmHg
†Difficult to determine during polypnea. During major seizures, the expiratory phase is at least twice longer than the inspiratory phase.
There are several criteria. It is not required that all criteria be met.
As seizure intensity increases, infants present with seesaw breathing, not shoulder breathing. During expiration and inspiration, distention 
and depression of the chest and abdomen repeat like a seesaw. Exclude intentional abdominal breathing.
Table　6　Symptoms during severe seizures in infantile asthma
1. Severe cough (occasionally vomiting) 8. Do not sleep (or cannot sleep)
2. Marked wheezing (occasionally reduced) 9. Cyanosis
3. Depression of suprasternal space and supraclavicular fossa and between ribs 10. Moaning
4. Tachypnea 11. Tachycardia
5. Nasal alar breathing 12. Ill-tempered
6. Seesaw breathing 13. Scream (excited)
7. Comfort when held (orthopnea) 14. Lowering level of consciousness
(i) Favorable response: If a favorable response is
obtained after the initial treatment, the patient should
be observed for an additional hour. If asymptomatic,
give instructions for future treatment and allow the
patient to go home. (ii) Insufficient response: If no re-
mission is achieved after 2 or more β2 stimulant inha-
lations, conduct an additional treatment. Treat infants
after hospitalization. (iii) No response or exacerba-
tion: If initial treatment results in unfavorable re-
sponse or exacerbates symptoms, treat the patient af-
ter hospitalization.
(3) Additional treatment for moderate seizure: Ad-
minister a steroid andor aminophylline. However,
caution should be exercised for adverse effects when
Nishimuta T et al.
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Fig.　2　Measures against acute seizures at outpatient departments. 
†(i) Children aged ≤5: Desirably performed by a specialist in childhood asthma. (ii) Infantile asthma: Avoid 
overdose. Avoid administration to infants with convulsive disorders. (iii) Caution should be exercised for 
patients with fever because of increased intermediate concentration.
Assessment of seizure intensity
Minor seizures
Occasionally accompanied
by mild wheezing and
retractive breathing 
SpO2 ≥ 96%
Moderate seizures 
Marked wheezing,
prolonged expiration,
and retractive breathing
92% ≤ SpO2 ≥ 95%
Major seizures 
Marked wheezing,
orthopnea, and
occasionally cyanosis
SpO2 ≤ 91%
Respiratory insufficiency
Reduced wheezing,
cyanosis, and
consciousness disorder
SpO2 < 91%
β2 stimulant inhalation
2 mL physiological saline
or DSCG 1A
+
inhalant solution
(salbutamol or procaterol) 
Infants 0.1-0.3 mL 
School children 0.2-0.4 mL
Ambulatory
treatment
No response
No response
Exacerbated
No response
Exacerbated
Insufficient
response
Repeated β2
stimulant inhalation
(every 20-30 min,
total up to 3 times) 
Oxygen inhalation
(if SpO2 < 95%)
Measures until hospitalization
(if cannot be immediately hospitalized) 
Oxygenation, β2 stimulant
inhalation Initial transfusion 
Systemic steroid administration
Hospitalization
Favorable
response Favorableresponse
Favorable
response
No
change
Insufficient
response
Insufficient
response
Favorable response
Disappearance of
wheezing and
retractive breathing 
Normal physical findings
SpO2 ≥ 97%
Allow patient to
go home and follow-up
Instruct patients about
medication at home,
timing of revisit, and
long-term management
Steroid administration
(intravenous infusion or
oral administration)
Aminophylline†
(intravenous or
continuous infusion)
Hospitalize patients
with infantile asthma
Table　7　Patients with moderate seizures who are discouraged from aminophylline administration (2-15 years old)
1. Patients with history of convulsions or those complicated by CNS diseases
2. Treatment for the following patients whose serum theophylline levels cannot be quickly measured
(i)  Patients with a history of adverse effects caused by aminophylline or theophylline.
(ii)  Patients periodically receiving sustained release theophylline, with serum theophylline level maintained at ≥15 μg/mL.
(iii)  Patients for whom it is difficult to determine the safety of intravenous aminophylline infusion, because the above 1) and 
the use status of theophylline are often unclear.
using aminophylline in infants.
a) Steroids: Administer a steroid via an intravenous
or oral route. See Table 8 for initial doses. Even for
patients with moderate seizures, consider combined
use with an intravenous steroid for early medical
treatment of patients: (i) receiving treatment step 3 or
above for long-term management; (ii) having a his-
tory of hospitalization due to asthma attack in the past
year; and (iii) receiving endotracheal intubation for
the treatment of asthma attack accompanied by im-
Childhood Asthma
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Table　8　Initial dosage of therapeutic agent for acute seizures
<2 years old 2-5 years old 6-15 years old
β2 stimulant
Nebulizer inhalation
With oxygen if SpO2 < 95%
0.1-0.3 mL of salbutamol or procaterol + 2 mL of physi-
ological saline or DSCG
0.2-0.4 mL of salbutamol or pro-
caterol + 2 mL of physiological 
saline or DSCG
Aminophylline
Intravenous infusion for ≥30 
min
Intravenous injection
<Hospitalize patients with major or 
more severe seizures>
No history of oral theophylline ad-
ministration: 3-4 mg/kg
History of oral theophylline admin-
istration: Reduce the dose of 3-4 
mg/kg if needed
<Additional treatment for moderate or more severe 
seizures>
No history of oral theophylline administration: 4-5 mg/
kg
History of oral theophylline administration: 3-4 mg/kg
Intravenous steroid injection
Slow intravenous injection for 
about 10 min or intravenous 
infusion for about 30 min
Hydrocortisone: 5 mg/kg
Prednisolone: 0.5-1 mg/kg
Methylprednisolone: 0.5-1 mg/kg
Hydrocortisone: 5-7 mg/kg
Prednisolone: 1-1.5 mg/kg
Methylprednisolone: 1-1.5 mg/kg
Oral corticosteroid
Prednisolone: 0.5-1 mg/kg/day 3 divided doses
<If oral prednisolone administration is impossible>
Betamethasone syrup or dexamethasone elixir: 0.05 mg (0.5 mL) /kg/day 2 divided doses
Rapid initial transfusion
Infants: 100-150 mL/h, ≥10 kg body weight: 200 mL/h
Until urination occurs
Table　9　Indications for hospital treatment
1. Major seizures and respiratory insufficiency
2. Moderate seizures
- Past history of severe seizures
- Not improved by ambulatory treatment for about 2 h
- Moderate seizures, continuing from the previous day and accompanied by sleep disturbance
 (Hospitalize patients with infantile asthma.)
3. Complications
- Pneumonia, atelectasis, mediastinal emphysema, subcutaneous emphysema, pneumothorax, etc.
paired consciousness or seizures.
b) Aminophylline: Conduct intravenous infusion of
an initial dose for 30 min or longer, followed by con-
tinuous infusion. The dosage is determined based on
the presence of oral administration of sustained re-
lease theophylline and the infant’s age. Desirably,
aminophylline is administered to children aged 5
years by a specialist in childhood asthma, and to chil-
dren aged <2 years after hospitalization. Aminophyl-
line is not recommended for the patients shown in
Table 7.
4.3. TREATMENT AND PROCEDURES IN
WARDS
Indications for hospital treatment are shown in Table
9. Patients with respiratory insufficiency require in-
tensive care with the assistance of emergency special-
ists and anesthesiologists.
4.3.1. Initial Treatment (Table 8)
Administer an inhaled β2 stimulant with a nebulizer
along with oxygen inhalation. Start initial transfusion
along with intravenous steroid administration (Table
10). Aminophylline can be administered concomi-
tantly. However, caution should be exercised for pa-
tients aged 0-2 years (Table 11).
(1) Favorable response: If symptoms are markedly
improved, follow-up the patient while performing β2
stimulant inhalation every 4-6 h and maintenance
transfusion. If needed, concomitantly conduct re-
peated steroid administration and continuous intrave-
nous aminophylline infusion.
(2) Insufficient or no response: If seizures are not
improved at 30 min after the start of treatment, pro-
ceed with an additional treatment.
4.3.2. Additional Treatment
Consider continuous isoproterenol (e.g., AsthpulⓇ)
inhalation.17-19 During this treatment, monitor blood
pressure, heart rate, respiratory rate, SpO2, etc. Inha-
lation is very effective, whose effects can usually be
noted within 30 min. Periodically conduct intravenous
Nishimuta T et al.
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Table　10　Systemic steroid administration
Intravenous
Initial dose Routine dose
2-15 years old <2 years old 2-15 years old <2 years old
Hydrocortisone 5-7 mg/kg 5 mg/kg
5-7 mg/kg
Every 6 h
5 mg/kg
Every 6-8 h
Prednisolone 1-1.5 mg/kg 0.5-1 mg/kg
0.5 mg/kg
Every 6 h
0.5-1 mg/kg
Every 6-12 h 
(max: 2 mg/kg/day)
Methylprednisolone 1-1.5 mg/kg 0.5-1 mg/kg
1-1.5 mg/kg
Every 4-6 h
0.5-1 mg/kg
Every 6-12 h
Oral
Prednisolone 0.5-1 mg/kg/day (3 divided doses)
If oral prednisolone administration is difficult, administer 0.5 mL (0.05 mg) /kg/day of betamethasone syrup or dexamethasone 
elixir (2 divided doses).
Intravenous administration: Intravenous injection for about 10 min or intravenous infusion for about 30 min.
Precautions: (i) Hydrocortisone: Limit the use to several days because of mineralocorticoid effects. (ii) Intravenous administration may
cause immediate allergic reaction. (iii) Limit the use to 3 days a month or several times a year. If these limits are exceeded, refer to a spe-
cialist in childhood allergy.
Table 11　Precautions for aminophylline injection for seizures caused by infantile asthma
- If β2 stimulants or steroids are not effective for major seizures or respiratory insufficiency, theophylline should be prescribed by 
a specialist.
- Do not prescribe theophylline for convulsive disorders, such as febrile convulsions and epilepsy.
- If there is fever, carefully refer to indications.
- Determine dosage based on 10 μg/mL of serum level. Monitor serum level as needed. Adjust dosage as needed, with an up-
per limit of 15 μg/mL.
- Theophylline clearance is reduced by fever, viral infection, diet, concomitant drugs, etc. In some cases, serum levels are ele-
vated.
steroid administration (see Table 10). Routinely, ster-
oid administration can be discontinued within several
days after remission.
4.3.3. Treatment of Respiratory Insufficiency
Respiratory insufficiency results in the alleviation and
disappearance of wheezing and causes severe cyano-
sis, and may be accompanied by urinary and fecal in-
continence and unconsciousness. Analyze arterial
blood gases to assess respiration and examine the
presence of complications that preclude treatment
(subcutaneous emphysema, mediastinal emphysema,
atelectasis, pneumonia, pneumothorax, etc.). There is
no definite indication for artificial respiratory manage-
ment. Check the following signs:
(i) reduced respiratory sounds and wheezing;
(ii) impaired consciousness resulting in somno-
lence or coma;
(iii) <60 mmHg PaO2 (<90% SpO2) even after suffi-
cient oxygen inhalation;
(iv) elevated PaCO2 (65 mmHg or 5 mmHg
h).
5. BASICS OF LONG-TERM MANAGEMENT
OF CHILDHOOD ASTHMA
5.1. SEVERITY DETERMINATION AND CONTROL
ASSESSMENT OF CHILDHOOD ASTHMA
5.1.1. Severity Determination
The severity of disease in patients not on long-term
management agent is shown in Table 12. If a long-
term management agent is already administered, de-
termine the “true severity” considering the present
treatment step (Table 13). For example, if the “appar-
ent severity” of a patient in treatment step 2 is mild
persistent, determine the “true severity” as their in-
tersection point, i.e., moderate persistent. Patients
with symptoms not controlled in treatment step 4,
whose apparent severity is moderatesevere persis-
tent is determined as the most severe persistent.
A comparison of severity determination between
children and adults demonstrate one-stage differ-
ences: mild and intermittent, mild persistent, and
moderate persistent in adults correspond to mild per-
sistent, moderate persistent, and severe persistent in
Childhood Asthma
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Table 12 Severity classifi cation of childhood bronchial asthma based on clinical symptoms before treatment
Severity Severity and frequency of symptoms
Intermittent
- Cough and mild wheezing seasonally occur several times a year.
- Although occasionally accompanied by dyspnea, the symptom is improved in a short time with a β2
stimulant of single use.
Mild persistent
- Cough and mild wheezing occur once or more a month or less than once a week.
- Although occasionally accompanied by dyspnea, the symptoms continue for a short time and rarely 
disturb daily life.
Moderate persistent
- Cough and mild wheezing occur once or more a week. The symptoms do not continue every day.
- The symptoms may become moderate or major seizures and disturb everyday life.
Severe persistent
- Cough and mild wheezing continue every day.
- The symptom may become moderate or major seizures once or twice a week and disturb everyday 
life and sleep.
Most severe persistent
- Even if treatment for severe and persistent symptoms is performed, the symptom continues.
- Moderate or major seizures at night cause frequent consultation after surgery hours and repeated 
hospitalization, and restrict daily life.
Table　13　Severity of childhood bronchial asthma, determined based on present treatment step
Severity based on present treatment step (true severity)
Treatment step
Severity based on 
symptoms alone 
(apparent severity)
Treatment 
step 1
Treatment 
step 2
Treatment 
step 3
Treatment 
step 4
Intermittent
- Cough and mild wheezing seasonally occur several times a 
year.
- Although occasionally accompanied by dyspnea, the symp-
toms are improved in a short time with a β2 stimulant of single 
use.
Intermittent Mild persistent
Moderate 
persistent
Severe 
persistent
Mild persistent
- Cough and mild wheezing occur once or more a month or less 
than once a week.
- Although occasionally accompanied by dyspnea, the symp-
toms continue for a short time and rarely disturb daily life.
Mild 
persistent
Moderate 
persistent
Severe 
persistent
Severe 
persistent
Moderate persistent
- Cough and mild wheezing occur once or more a week. The 
symptoms do not continue every day.
- The symptoms may become moderate or major seizures and 
disturb everyday life and sleep.
Moderate 
persistent
Severe 
persistent
Severe 
persistent
Most severe 
persistent
Severe persistent
- Cough and wheezing continue every day.
- The symptoms may become moderate or major seizures once 
or twice a week and disturb everyday life and sleep.
Severe 
persistent
Severe 
persistent
Severe 
persistent
Most severe 
persistent
children, respectively.
5.1.2. Treatment Goal of Childhood Asthma
To the pre-existing treatment goals 1 to 6, JPGL2008
added a seventh goal: improvement of airway hyper-
responsiveness, aiming at final remission and cure
(Table 14). It is difficult to conduct an airway hyperre-
sponsiveness test in non-specialized medical institu-
tions. Thus, conduct treatment and management,
aiming at statuses indicating improvement of airway
hyperresponsiveness. For example, no exercise in-
duced asthma is induced during routine medical
treatment and no symptoms are induced by stimuli,
such as cold air and smoke.
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Fig.　3　C-ACT questionnaire. Adapted from the web page of Japanese Society of Pediatric Allergy and Clinical 
Immunology, http://zensoku.jp/check/check2.html#info.
Copyrighted material (all rights reserved)
Childhood Asthma Control Test
For children aged
4-11 years
Children answer the following questions.
(1) How are you feeling? Score
0 1 2 3Very bad Bad Good
(2) How is asthma troubling you during running, exercise, or sports?
Very good
Guardians answer the following questions.
(5) How many days did asthma symptoms occur in the daytime in these four weeks? Score
5 4 3 2 00 days 1-3 days 4-10 days 119-24 days Every day11-18 days
(6) How many days did wheezing occur because of asthma in the daytime in these four weeks?
5 4 3 2 00 days 1-3 days 4-10 days 119-24 days Every day11-18 days
(7) How many days did your child awake because of asthma in the nighttime in these four weeks?
5 4 3 2 00 days 1-3 days 4-10 days 119-24 days Every day11-18 days
0 1 2 3
Troubled
and
hateful
Slightly
troubled
but OK
No trouble
So troubled that
I cannot do
what I want to do
(3) Do you cough because of asthma?
0 1 2 3
Yes,
almost
always
Yes,
occasionally
No,
not at all
Yes,
always
(4) Do you awake at night because of asthma?
0 1 2 3
Yes,
almost
always
Yes,
occasionally
No,
not at all
Yes,
always
Show the results to physician!
See the back to check
childhood asthma control
status based on total score. Total score
Table　14　Treatment goal of childhood bronchial asthma
Besides fi nal remission and cure, the aims of daily control are:
1. Reduced or no need for β2 stimulants of single use.
2. No symptom day and night.
3. No absence from school.
4. Normal daily life, including sports.
5. Stable PEF rate.
6. Almost normal pulmonary function.
7. Improved airway hyperresponsiveness (no symptom provocation after exercise, cold air inhalation, etc.).
5.1.3. Control of Asthma
Complete control is a status in which the aim of
asthma treatment is achieved. Favorable control can
be achieved by selecting an appropriate treatment
step based on severity. However, insufficient treat-
ment, inappropriate medication, and inevitable exac-
erbation factors result in poor control. The asthma
control test was developed for treatment and manage-
ment aimed at favorable control.
(1) Childhood Asthma Control Test (C-ACT)20: C-
ACT is a childhood asthma control test for children
aged 4-11 years (Fig. 3). The test consists of 7 ques-
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Fig.　4　JPAC questionnaire. Modifi ed from the web page of Japanese Society of Pediatric Allergy and 
Clinical Immunology, http://zensoku.jp/check/check2.html#info.
Inhaled corticosteroid
 (i)  Flutide Diskus (50 μg), (100 μg), (200 μg) [inhalation frequency a day:  Twice]
 (ii)  Flutide Rotadisk (50 μg), (100 μg), (200 μg) [inhalation frequency a day:  times]
 (iii)  Flutide Aerosol (50 μg), (100 μg) [inhalation frequency a day:  times]
 (iv)  Qvar (50 μg), (100 μg) [inhalation frequency a day:  times]
 (v)  Pulmicort inhalant solution (0.25 mg), (0.5 mg) [inhalation frequency a day:  times]
 (vi)  Adoair (50/100 mg) [inhalation frequency a day:  times]
Severity Determination of Childhood Asthma and Asthma Control Test
Answer the following questions 1-5 about asthma symptoms and troubles in daily life in the last month.
Check the appropriate boxes about frequency and severity.
1. How many days did wheezing occur in the last month? 
Not at all (3) Continuedevery day (0) 
Once or more a week,
not every day (1)
Once or more a month,
less than once a week (2)
2. How often did seizures accompanied by dyspnea (choking) occur in the last month? 
Not at all (3) Continued almostevery day (0) 
Frequently occurred
and maintained (1)
Occasionally occurred
and not maintained (2)
4. Are you troubled with wheezing during exercise or romping about? 
Not at all (3) Always,and troubled (0) 
Frequently,
and troubled (1)
Slightly,
but not troubled (2)
5. How many days did you use an inhalant, oral medicine, or patch for seizures in the last one month? 
    (The term "medicines" of this questionnaire means medicines used not for prevention, but for the
     treatment of seizures, including cough and wheezing.)
6. Show the name of a long-term management agent (prophylactic agent) for asthma, being used now
    (Circle to the agents). If using an inhaled corticosteroid, show inhalation frequency a day.
Not at all (3) Used daily (0) Several times a week,not every day (1)
Less than
once a week (2)
3. How many days did you awake because of asthma at night in the last month? 
Not at all (3) Every day (0) Once or more a week,not every day (1)
Occasionally, less
than once a week (2)
Leukotriene receptor antagonists: (i) Onon, (ii) Singulair, (iii) Kipres 
Long-acting β2 agonists: (i) Serevent Diskus, (ii) Serevent Rotadisk 
Sustained release theophylline:  (i) Theodur, (ii) Slo-bid, (iii) Theolong, (iv) Uniphyl 
Intal inhalation:  (i) inhalant solution, (ii) Intal capsule (E-haler), (iii) Aerosol 
- Severity: Moderate and persistent (mild and persistent symptoms at the treatment step 2) 
- Control status: JPAC 12 points (favorable insufficient control) 
- Measure: Treatment step 3, ICS 100 μg × 2
tions, of which diseased children answer the first 4
and their parents answer the remaining 3. The first 4
questions are face scale to allow children to answer
them easily. Scoring is as follows: 27 points is perfect
control;20 is favorable control; and <20 is poor con-
trol. Long-term management is conducted with a goal
of 27 points. For children aged12, the Asthma Con-
trol Test (ACT) for adults can be used.
(2) Japanese Pediatric Asthma Control Program
(JPAC)21: Severity and control statuses can be as-
sessed by JPAC. The former allows the selection of
treatment step according to the guidelines. Step-up
and step-down are determined using the latter. Scor-
ing is as follows: 15 points is complete control; 12-14
is favorable (insufficient) control; and 11 is poor
control. Conduct treatment and management with a
goal of 15 points.
Figure 4 shows an example of JPAC. In this exam-
ple, treatment step 2 is conducted with question 6.
“Mild persistent” is circled for the questions 1-3. True
severity is determined as “moderate persistent”
based on Table 13. JPAC score, a total score of ques-
Nishimuta T et al.
158 Allergology International Vol 60, No2, 2011 www.jsaweb.jp
Table　15　Major inhalation antigens and food antigens
1. Inhalation antigens
- House dust (HD)
- Mites (DP or DF)
- Cedar pollen
- Cat (dander)
- Dog (dander)
- Fungi (Alternaria, Aspergillus, Cladosporium, Penicillium)
- Other pollens (cypress, orchard grass, ragweed, mug-
wort, etc.)
- Other pets (hamster, guinea pig, and rabbit)
- Others (cockroach, chironomid midge)
2. Food antigens
- Egg white, egg yolk, ovomucoid
- Cow’s milk, casein, α-lactalbumin, β-lactoglobulin
- Wheat
- Cereals, such as soybean, rice, and buckwheat
- Fish and shellfi shes
- Fruits
tions 1-5, is 12. Thus, this case is determined as insuf-
ficient control. Since the true severity is moderate
persistent, step up to treatment step 3.
(3) Objective assessment of control status: Appro-
priate assessment of the statuses of diseased children
is important for long-term management. For this pur-
pose, asthma diary and measurement of peak expira-
tory flow are utilized. In addition, assessment of the
peripheral airway using a flow volume curve is impor-
tant.
5.2. AVOIDANCE OF EXACERBATION FACTORS
Most patients with childhood asthma have an atopic
diathesis and produce specific IgE antibodies to mites
in house dust. Tests are needed to examine specific
IgE antibodies to other allergens and changes in spe-
cific IgE antibody titers during treatment and man-
agement.
5.2.1. Allergy Tests and Assessment
Mean total IgE values vary with age. High values are
those that exceed the mean + 2SD. Typical anti-
gens are shown in Table 15. To investigate the aller-
gens of childhood asthma, begin by presuming envi-
ronmental antigens by history taking to select inspec-
tion items. Routine inspection methods include skin
tests and measurement of serum specific IgE antibod-
ies in the blood, however even if positive for specific
IgE antibodies, not all cause asthma.
5.2.2. Instructions for Environmental Improve-
ment
Cleaning rooms with a vacuum cleaner is an impor-
tant measure against mite antigens. Using a wood or
cushioned floor as flooring material is more effective.
Measures for bedclothes are also important; bed-
clothes are preferably vacuumed at least once a week.
Sensitization to pets (e.g., cats, dogs, and rodents)
may induce seizures, so contact with these animals
should be avoided.
5.2.3. Instructions for Smoking Cessation
Smoking, both active and passive smoking, is an ex-
acerbation factor of asthma. Smoking of pregnant
mothers affects the respiratory function of their chil-
dren after birth.22 Parents with smoking habits must
be instructed about the need for smoking cessation
as a vital component of childhood asthma treatment.
If the children themselves are smoking, instruct them
about the adverse influences on treatment and con-
duct smoking cessation therapy.
5.3. LONG-TERM MANAGEMENT BY MEDICA-
TION
5.3.1. Formulations and Characteristics of Long-
Term Management Agents (Controllers)
Agents continuously used to reduce and eliminate
asthma symptoms, improve QOL, and normalize and
maintain respiratory function are called long-term
management agents (controllers). Long-term man-
agement agents should have antiinflammatory ef-
fects. Agents with antiinflammatory effects include
steroids, leukotriene receptor antagonists (LTRAs),
and theophylline. Systemic steroid administration for
long-term management is limited to the most severe
cases because of adverse effects. Inhaled corticoster-
oids are routinely used. Long-acting β2 agonists
(LABAs) are concomitantly used with an inhaled cor-
ticosteroid for long-term management, and are not
used alone.23
(1) Inhaled corticosteroid (ICSs): ICSs potently
suppress airway inflammation and play an important
role for long-term management. As airway inflamma-
tion is ameliorated, subjective symptoms, respiratory
function, and airway hyperresponsiveness impro-
ve,24,25 and hospitalization due to seizures and deaths
from asthma decrease.26 However, no evidence has
been obtained regarding increased natural outgrow
of symptoms. ICSs indicated for children are shown
in Table 16. A compounding agent of ICS and LABA
can be used for children aged 5 years. Select
agents depending on ages or inhalation methods to
achieve efficient inhalation.
(2) Leukotriene receptor antagonists (LTRAs):
LTRAs inhibit bronchoconstriction and airway inflam-
mation,27 and are effective for long-term manage-
ment. LTRAs indicated for childhood asthma are
shown in Table 17. In many cases, LTRAs improve
respiratory function and reduce seizures within 1-2
weeks after administration. In patients with mild
symptoms, LTRAs are as effective as ICSs.28,29 Effi-
cacy of LTRAs as additional agents for ICSs has been
demonstrated.30-32
(3) Sustained release theophylline (SRT): SRT,
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Table　16　Inhaled corticosteroids indicated for children
Formulation Generic name Trade name Contents Remarks
pMDI
Fluticasone FlutideⓇ Aerosol 50,100 μg Maximum 200 μg/day
Beclomethasone QvarⓇ 50,100 μg Maximum 200 μg/day
DPI
Fluticasone FlutideⓇ Diskus 50,100 μg Maximum 200 μg/day
FlutideⓇ Rotadisk 50,100 μg Maximum 200 μg/day
Budesonide PulmicortⓇ Turbuhaler 100,200 μg Maximum 800 μg/day
Suspension
Budesonide PulmicortⓇ inhalant solution 0.25,0.5 mg Maximum 1.0 mg/day
≥0.5 to <5 years old
Compound with a long-acting β2 agonist
pMDI
Fluticasone AdoairⓇ 50 Aerosol 50 μg Maximum 200 μg/day
Salmeterol 25 μg Maximum 100 μg/day
DPI
Fluticasone AdoairⓇ 100 Diskus 100 μg Maximum 200 μg/day
Salmeterol 50 μg Maximum 100 μg/day
800 μg of BUD is equivalent in titer to 400 μg of FP and BDP.
Table　17　Leukotriene receptor antagonists indicated for children and their dosages
Generic name Trade name Formulation Dose
Pranlukast
OnonⓇ Dry syrup 7 mg/kg/day (<450 mg a day)
Capsule 2 divided doses
Montelukast
SingulairⓇ Chewable tablet 5 Routinely administer 5 mg once a day to children aged ≥6 years be-
fore bedtime.
Fine granule 4 mg Routinely administer 4 mg once a day to children aged 1-6 years 
before bedtime.
KipresⓇ Chewable tablet 5 Routinely administer 5 mg once a day to children aged ≥6 years be-
fore bedtime.
Fine granule 4 mg Routinely administer 4 mg once a day to children aged 1-6 years 
before bedtime.
Table　18　Precautions for long-term management with a sustained release theophylline for infantile asthma
- Consider the use of a sustained release theophylline as an additional treatment for patients at treatment step 3 or above.
- Do not perform long-term management with a sustained release theophylline in children aged <6 months.
- Avoid the use of a sustained release theophylline even for patients aged ≥6 months if they have epilepsy or febrile convulsion.
- Desirably, instruct patients to reduce dosage or discontinue administration if fever occurs.
- During the administration of a sustained release theophylline, caution should be exercised for the combined use of other 
agents (e.g., erythromycin, and clarithromycin), which reduces theophylline clearance and raises its serum level.
- Caution should be exercised for the combined use of antiallergics for infantile asthma. Reportedly, antiallergics with histamine
H1 antagonist action actively migrate to the CNS to lower convulsant threshold.
- Avoid the use of an aminophylline suppository.
which has a bronchodilator action and an antiinflam-
matory effect, is used as a controller. The dosage of
theophylline is determined considering factors that
influence metabolisms, such as individual differences,
infection, meal contents, and concomitant drugs. Cau-
tion should be exercised for elevated serum theophyl-
line level resulting from decreased clearance caused
by fever during viral infection. In infants, a convulsive
status epilepticus associated with theophylline ad-
ministration causes a problem.33 Precautions for use
are shown in Table 18.
(4) Long-acting β2 agonists (LABAs): Since β2
stimulants have no inhibitory effect on airway inflam-
mation, use LABAs concomitantly with ICSs. Besides
inhaled LABAs, transdermal patches34,35 and oral
medicines are available as LABAs. After pasting of
transdermal tulobuterol patch, serum tulobuterol
level is maintained for 24 h. Use them concomitantly
with ICSs for long-term management.
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Table　19　Pharmacotherapy plan for long-term management of childhood bronchial asthma (<2 years old)
Treatment step 1 Treatment step 2 Treatment step 3＃ Treatment step 4＃
Basic 
treatment
None (pharmacotherapy 
according to seizure 
intensity)
- Leukotriene receptor 
antagonist † and/or
- DSCG inhalation (2-4 
times/day) ‡,‖
- Inhaled corticosteroid § 
(100 μg/day FP or BDP, 
0.25-0.5 mg/day BIS)
- Inhaled corticosteroid§ 
(150-200 μg/day FP or 
BDP, 0.5-1.0 mg/day BIS)
One of the followings or both
- Leukotriene receptor 
antagonist†
- DSCG inhalation ‡,‖
(2-4 times/day)
Additional 
treatment
- Leukotriene receptor 
antagonist† and/or
- DSCG inhalation (2-4 
times/day)‡, ‖
- Inhaled corticosteroid § 
(50 μg/day FP or BDP, 
0.25 mg/day BIS)
Either or both of the 
followings:
- Leukotriene receptor 
antagonist †
- DSCG inhalation (2-4 
times/day) ‡,‖
- β2 stimulant ‖ (2 times/
day, patch or p.o. 
before bedtime)
Sustained release 
theophylline¶ (in mind)
 (serum level: 5-10 μg/
mL)
- β2 stimulant‖ (2 times/day, 
patch or p.o. before 
bedtime)
- Sustained release theoph-
ylline¶ (in mind) (serum 
level: 5-10 μg/mL)
† Antiallergics indicated for other childhood asthma symptoms: chemical mediator release suppressants, some histamine H1 antagonists, 
and Th2 cytokine inhibitors.
‡ To inhale a DSCG inhalant solution using a nebulizer, inhale it with a small amount (0.05-0.1 mL) of β2 stimulant as needed.
§ FP: fl uticasone propionate, BDP: beclomethasone dipropionate, BIS: budesonide inhalation suspension.
Inhale FP and BDP using a spacer with a mask. Inhale BIS with a nebulizer.
¶ Do not use this agent for children aged <6 months. Caution should be exercised for indications. Do not use this agent for convulsive 
disorders. Desirably, instruct patients to reduce dosage or discontinue administration if fever occurs.
‖ Once symptom is controlled, discontinue the administration of a β2 stimulant.
＃ Desirably, perform treatment step 3 or above according to the instructions and management of a specialist in childhood allergy. A spe-
cialist treats a patient with asthma, insufficiently controlled by treatment step 4.
5.3.2. Long-Term Management Plan
(1) Selection of treatment step based on severity:
In a pharmacotherapy plan for long-term manage-
ment, determine severity based on symptoms and
their frequency for last 1-2 months (see Table 12) and
select a long-term management agent for the treat-
ment step selected based on the severity. The phar-
macotherapy plan for long-term management is di-
vided into age groups: <2, 2-5, and 6-15 years old (Ta-
ble 19-21).
Select a long-term management agent for a step de-
termined based on true severity (Table 13). During
treatment, examine the control status using a control
questionnaire, etc., to maintain complete control. If
control is insufficient or poor, achieve complete con-
trol through an additional treatment or step-up. If
complete control is achieved for 3 months or longer,
reduce the dosage to the lowest recommended one to
maintain control.
(2) Therapeutic agents according to control stat-
uses: Determine control statuses referring to asthma
symptoms written in an asthma diary, difficulties in
daily life, and usage of short-acting β2 agonists, PEF
monitoring,36,37 etc. Favorable control is indicated by
20% diurnal variation in PEF rate or 80% of the
best value. C-ACT and JPAC, described above, are
also appropriate for the assessment of control status.
If control is insufficient or poor, examine the appro-
priateness of medication and allergen avoidance or
the effects of psychosocial factors. If no effects are ob-
tained in treatment step 4, consider hospitalization for
treatment38 or oral corticosteroid administration for
the most severe persistent cases.
If symptoms are controlled for 3 months or longer,
consider step-down for a period based on severity,
history of disease, respiratory function, and medica-
tion. If asthma symptoms are controlled below inter-
mittent type and respiratory function is favorable af-
ter reduction to the lowest recommended dosage,
treatment can be discontinued. At present, there are
no criteria for discontinuation. If symptoms remit
(i.e., a status with neither treatment nor symptoms),
the patient should be followed-up. Here, the remis-
sion does not mean cure.
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Table　20　Pharmacotherapy plan for long-term management of childhood bronchial asthma (2-5 years old)
Treatment step 1 Treatment step 2 Treatment step 3 Treatment step 4
Basic 
treatment
Pharmacotherapy 
according to seizure 
intensity
- Leukotriene receptor 
antagonist† and/or
- DSCG†,‖ ,＃ or Inhaled 
corticosteroid‡
 (in mind)
 (50-100 μg/day FP or 
BDP, 0.25 mg/day BIS)
Inhaled corticosteroid‡ 
(100-150 μg/day FP or 
BDP, 0.5 mg/day BIS)
Inhaled corticosteroid ‡ ,¶ 
(150-300 μg/day FP or 
BDP, 1 mg/day BIS)
Either or both of the follow-
ings:
- Leukotriene receptor 
antagonist
- DSCG‖, ＃
- Sustained release theoph-
ylline§
- Long-acting β2 agonist ＃
(patch/oral/inhalation††)
Additional 
treatment
- Leukotriene receptor 
antagonist† and/or
- DSCG†
- Sustained release the-
ophylline§
Either or both of the 
followings:
- Leukotriene receptor 
antagonist
- DSCG‖,＃
- Sustained release the-
ophylline§
- Long-acting β2 agonist ＃
 (patch/oral/inhalation††)
† Antiallergics indicated for other childhood asthma symptoms: chemical mediator release suppressants, histamine H1 antagonists, and 
Th2 cytokine inhibitors.
‡ FP: fl uticasone propionate, BDP: beclomethasone dipropionate, BIS: budesonide inhalation suspension.
§ Caution should be exe rcised for the adverse effects of a sustained release theophylline, accompanying elevated serum level due to 
fever.
¶ For patients with symptoms that cannot be controlled by treatment step 4, perform treatment, including oral corticosteroid administra-
tion, under the management of a specialist.
‖ To inhale a DSCG inhalant solution using a nebulizer, inhale it with a small amount (0.05-0.1 mL) of β2 stimulant as needed.
＃Once symptom is controlled, discontinue the administration of a β2 stimulant.
†† Children who can inhale with a dry powder inhaler (DPI).
Notes) A compounding agent of salmeterol xinafoate and fl uticasone propionate (SFC) is indicated for children aged ≥5. Thus, in children
aged 5, the compounding agent can be used from treatment step 3 (additional treatment). However, it is not shown in this table because of 
insufficient evidence.
6. INHALERS AND SPACER
Inhalation therapy is critical and effective for daily
management and seizure treatment of childhood
asthma. Understand the characteristics (i.e., merits
and demerits) of inhalers for their selection based on
the child’s status.
6.1. INHALERS
Inhalers are classified into nebulizers and metered
dose inhalers. Three types of nebulizers, based on
their drive systems, are available: jet, ultrasonic, and
mesh. Metered dose inhalers include the pressurized
metered dose inhaler (pMDI) and the dry powder in-
haler (DPI). Table 22 shows their merits and demer-
its. Select an inhaler considering agents, spacer,
child’s age, severity, compliance, economic condi-
tions, etc.
(1) Nebulizer: Since respiratory control is not re-
quired during inhalation, a nebulizer can be used re-
gardless of age, if a mask is used. Jet nebulizers are
most widely used for inhalation therapy of asthma.
Mesh nebulizers are a subtype of ultrasonic nebuliz-
ers. Mesh nebulizers are lightweight, power saving,
and have high spray capacity. Ultrasonic nebulizers
are unsuitable for inhaling an anti-asthmatic drug be-
cause of heat effects on agents, concentration
changes in a drug tank, etc.
(2) Use of nebulizers: The child should inhale at a
resting respiratory rate in a sitting position. Children,
old enough to oral breathing, inhale with a mouth-
piece, attached to the nozzle of nebulizer, put in the
mouth. For infants, use spray with a mask, attached
to the nozzle, to cover the mouth and nose. Airtight-
ness greatly influences inhalation efficiency. Inhala-
tion efficiency is reduced by nasal inhalation or cry-
ing.39,40
(3) Metered dose inhalers: pMDI and DPI are
available. If no spacer is used for pMDI, synchronize
spray and inhalation. Even in infants, for whom spray
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Table　21　Pharmacotherapy plan for long-term management of childhood bronchial asthma (6-15 years old)
Treatment step 1 Treatment step 2 Treatment step 3 Treatment step 4
Basic 
treatment
Pharmacotherapy 
according to seizure 
intensity
Inhaled corticosteroid‡ 
(100 μg/day FP or BDP, 
100-200 μg/day BUD) 
or
- Leukotriene receptor 
antagonist† and/or
- DSCG†
Inhaled corticosteroid‡ 
(100-200 μg/day FP or 
BDP, 200-400 μg/day 
BUD)
Inhaled corticosteroid‡,§ 
(200-400 μg/day FP or 
BDP, 400-800 μg/day 
BUD)
Either or both of the 
followings:
- Leukotriene receptor 
antagonist
- Sustained release the-
ophylline
- DSCG
- Long-acting β2 agonist¶ 
(inhalation/patch/oral)
or SFC‖
 (100/200 μg/day)
Additional 
treatment
- Leukotriene receptor 
antagonist† and/or
- DSCG†
Sustained release 
theophylline
Either or both of the 
followings:
- Leukotriene receptor 
antagonist
- Sustained release 
theophylline
- DSCG
- Long-acting β2 agonist ¶
(inhalation/patch/oral)
or switch to
- SFC‖ (50/100-
100/200 μg/day)
- Oral corticosteroid§
(short term and intermit-
tent in mind)
- Hospitalization (in mind)
† Antiallergics indicated for other childhood asthma symptoms: chemical mediator release suppressants, histamine H1 antagonists, and 
Th2 cytokine inhibitors.
‡ Inhaled corticosteroids: FP (fl uticasone propionate), BDP (beclomethasone dipropionate), or BUD (budesonide). BUD dose, converted 
at a ratio of FP/BUD: BUD = 1: 2, is indicated. If symptom can be well controlled by treatment step 2, BUD dose can be reduced to 100 μg/
day once a day.
§ For patients with symptoms that cannot be controlled by treatment step 4, perform treatment, including oral corticosteroid administra-
tion, under the management of a specialist.
¶  Once symptom is controlled, discontinue the administration of a β2 stimulant.
‖ SFC: a compounding agent of salmeterol xinafoate and fl uticasone propionate. Salmeterol/fl uticasone dose is indicated. To use a com-
pounding agent, switch from FP or BDP. Avoid combined use with a long-acting β2 agonist. Leukotriene receptor antagonist, DSCG, or the-
ophylline can be used concomitantly.
and inhalation cannot be synchronized, pMDI can be
employed by using a spacer and a mask. Using DPI, a
patient inhales an agent by self inspiration. School
children or older adolescents can use DPI, because a
certain amount of inspiratory force is required and a
spacer and a mask cannot be used concomitantly.
Agents for metered dose inhalers, which can be used
for childhood asthma, are shown in Table 23.
6.2. SPACER
A spacer is an indispensable instrument for pMDI in
infants who cannot accurately perform the proce-
dures for synchronizing spray and inhalation. Con-
comitant use of a spacer allows inhalation at a normal
respiratory rhythm even without synchronizing spray
of an agent, thus increasing inhalation efficiency. In
addition, a spacer is useful in adsorbing large parti-
cles (5 μm) onto the inner wall of the spacer to pre-
vent deposition of excess agent in the oral cavity and
reduce adverse effects. In infants who cannot breathe
through the mouth, mask the nose and mouth to
maintain inhalation efficiency.
Many types of spacers are available. Select a spacer
with data assuring aerodynamic properties and clini-
cal usefulness and safety. The effectiveness of a
spacer is greatly influenced by concomitant agents
and procedures as well as the shape, structure, and
physical properties of the spacer. Thus, assessment
under various conditions according to certain criteria
should be established in the future.41-43
Precautions for using a spacer are shown in Table
24. To benefit from a spacer, mask the face closely
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Table　22　Inhalers and their characteristics
Type Merits Demerits System Merits Demerits
Nebulizer
Inhalable by 
normal respira-
tion; Usable for 
infants; Inhal-
able without 
fail; Easy 
adjustment of 
liquid medicine.
Large and expen-
sive inhalator; 
Time-consuming; 
Limited use of 
medicines; Need 
for power supply; 
Noisy.
Jet High durability Noisy; Relatively large size; 
Need for alternating current
source.
Ultrasonic Massive spray; Quiet. Denaturation of medicine;
Excessive water inhalation; 
Unsuitable for spraying a
small amount; Large size; 
Cannot inhale a steroid 
suspension.
Mesh Quiet; Lightweight 
and small size; Run 
on batteries.
Durability unknown; Few in-
struments available.
Metered 
dose inhaler 
(MDI)
Lightweight 
and small size; 
Portable; No 
need for 
special device; 
No noise; No 
need for power 
supply; Quick 
inhalation.
Complicated 
inhalation proce-
dures; Unstable 
inhalation; Difficult 
usage for juveniles; 
Minor volume 
adjustment impos-
sible; Tendency of 
repeated excessive 
use; Risks of 
overdose.
Pressurized 
metered 
dose inhaler 
(pMDI)
Synchronization can 
be omitted by using 
a spacer; Portable.
Need for synchronization of 
inhalation and spray; Need 
for sufficient shaking and 
mixing before use; Need for 
spray solvent.
Dry pow-
der inhaler 
(DPI)
No need for synchro-
nization of inhalation 
and spray; Easy 
handling and man-
agement; No need 
for spray solvent.
Need for inhalation power;
Unusable for juveniles; Lim-
ited types of agent.
Table　23　Metered dose inhalers
Pressurized metered dose inhaler 
(pMDI)
β2 stimulants Salbutamol; Sultanol® Inhaler, Airomir® Aerosol, Pro-
caterol; Meptin® Air, Meptin® Kid air
Inhaled corticosteroids Beclometasone; Qvar®
Fluticasone; Flutide® Aerosol
Anticholinergics Ipratropium; Atrovent® Aerosol
Compounding agent of inhaled 
corticosteroid/β2 stimulant
Fluticasone/salmeterol; Adoair® Aerosol
Antiallergics DSCG; Intal® Aerosol
Dry powder inhaler (DPI)
Inhaled corticosteroids Fluticasone; Flutide® Rotadisk, Flutide® Diskus
Pulmicort® Turbuhaler
β2 stimulants Salmeterol; Serevent® Rotadisk, Serevent® Diskus,
Procaterol; Meptin® Clickhaler
Compounding agent of inhaled 
corticosteroid/β2 stimulant
Fluticasone/salmeterol; Adoair® Diskus
Antiallergic DSCG capsule; Intal® + E-haler®
without leakage and prevent static electricity.
7. PROBLEMS IN DAILY LIFE AND THEIR
MANAGEMENT
7.1. EXERCISE INDUCED ASTHMA (EIA)
(1) EIA: EIA is a phenomenon in which wheezing
and dyspnea occur temporarily during exercise. Its
pathology is unclear. Cooling in the airway, caused
by hyperventilation during exercise44, and elevated
osmolarity in the airway epithelium, caused by water
loss, are potential causes.45,46 Increased airway tem-
perature after exercise may also be involved.47
(2) Diagnosis: If coughing, wheezing, and dyspnea
occur during or after exercise, a diagnosis of EIA
may be made. Conduct an exercise stress test to
quantitate EIA.48,49
(3) Severity: The maximum decreasing rate of
forced expiratory volume in one second (FEV1) after
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Table　24　Precautions for using a spacer
1. After spraying, inhaled as immediately as possible.
2. Do not rub a plastic spacer (to prevent static electricity).
3. Water washing and natural drying are desirable.
4. Avoid spraying one inhalation dose multiple times.
Table　25　Effective measures for EIA prevention
1. Warming up
2. Prevention by medication
(i)  β2 stimulants
(ii)  DSCG
(iii)  Leukotriene receptor antagonists
(iv)  Others
3. Other prophylaxes
(i)  Mask
(ii)  Routine training
exercise is higher in patients with more severe
asthma. This serves as a parameter to determine the
severity.50 Since EIA is also correlated with airway
hyperresponsiveness, history taking of EIA is impor-
tant to determine the appropriateness of treatment
step.
(4) Prevention: To prevent EIA, select the treat-
ment step based on severity. Once it has occurred,
prevent EIA using the procedures in Table 25.
(5) Exercise instructions: Do not restrict exercise
because it benefits the child’s growth in various ways.
Parents, kindergarten teachers, school officials,
school physicians, and attending physicians should
collaborate to take measures so that children with
asthma can safely participate in exercise at kinder-
gartens and schools. Specific procedures are shown
in Table 26.
7.2. PARTICIPATION IN EVENTS AT KINDER-
GARTEN AND SCHOOLS
Make supportive plans for extracurricular studies and
club activities, such as school trips, school camps,
and excursions in cooperation with kindergartens
and schools so that children with asthma can partici-
pate whenever possible. Instruct children with
asthma and their parents beforehand about cautions
for participating in events and measures against sei-
zures.
(1) If children with asthma develop seizures when
participating in events, make them inhale a bron-
chodilator early because of the special situation. De-
pending on the statuses of daily seizures and medica-
tion, consider a dose increase of an ICS and short-
term administration of an oral corticosteroid when
participating in events.
(2) Hand disease records to attending physicians
so that patients can receive appropriate treatments at
nearby medical institutions, when seizures occur dur-
ing travel.
(3) If allergies occur after contact with an animal,
caution should be exercised for contact with animals
at zoos, etc.
(4) Stand on the windward side to avoid the smoke
from fireworks or campfires.
(5) Instruct roommates to refrain from wrestling
and pillow fights on the beds.
7.3. PRECAUTIONS FOR SCHOOL ACTIVITIES
(1) Since EIA is most likely to occur during a dead
run or a long-distance race, instruct patients to start
slowly.
(2) If allergies occur after contact with domestic
animals, do not allow the children take care of ani-
mals.
(3) Make class teachers explain to patient’s class-
mates about EIA, which slows the pace and may in-
terrupt exercise.
(4) Consider avoiding allergens and airway stimu-
lators during clean-up duty.
7.4. INSTRUCTION TABLE FOR SCHOOL LIFE
MANAGEMENT
In 2008, an instruction table for school life manage-
ment was created for allergic diseases. The allergic
diseases include asthma, atopic dermatitis, allergic
conjunctivitis, anaphylaxis and food allergies, and al-
lergic rhinitis. Disease types and treatments, precau-
tions for school life, emergency contact numbers, and
names of medical institutions and physicians should
be submitted to the schools (http:www.
gakkohoken.jp.bookbo0002.html).
8. PATIENT EDUCATION
To perform asthma treatment effectively, educate pa-
tients and their parents to be actively involved in
asthma treatment.51,52
(1) Infants (2-4 years old): Do not discomfort pa-
tients during treatment. Make them have interest in
the treatment. to be motivated. Encourage and com-
pliment inhalation to habituate them gradually.
(2) School age (from 5 years old to lower grades of
elementary school): Explain the pathology of asthma
to patients, using simple terms and metaphors, to
make them understand the need for treatment. In-
struct patients about abdominal breathing, PEF meas-
urement, etc., cheerfully as if they were playing some
kind of game.
(3) Prepuberty (upper grades of elementary sch-
ool): Instruct patients about the need for continuing
treatment without interruption. According to their un-
derstanding, educate them about pathophysiology
and treatment. Since it is difficult to make patients
take charge of treatment and management that their
parents have taken care of, compliment them to
achieve self-fulfillment and lead to self-management.
Childhood Asthma
Allergology International Vol 60, No2, 2011 www.jsaweb.jp 165
Table　26　Specifi c measures for exercise instructions
1. Prior information gathering
(i)  Relationship between the amount and contents of exercise and the degree and frequency of EIA
(ii)  Precautions for exercise by patients and people around them
(iii) Presence and contents of prophylactic agent before starting exercise
(iv) Measures for EIA, conducted by patients and people around them
2. Precautions for exercise
(i)  Consider pleasures for inexperienced participants who are not good at exercise.
(ii)  Check seizures and PEF rate on the day.
(iii) Check the contents and intensity of exercise.
· Adjust exercise intensity to allow for pleasant participation.
· If seizures occurred at previous night or on the day, adjust amount of exercise.
· If participation in exercise is difficult
Change clothes into gym suit, and consider participation as a recorder, measurer, referee, etc.
(iv) Check medication before starting exercise.
(v)  Check EIA measures by patients and people around them.
3. Precautions after starting exercise
(i)  Use of prophylactic agent
(ii)  Sufficient warming up
 (Causing and alleviating mild EIA before exercise may reduce the risks of EIA during exercise)
(iii) Perform interval training and repetition training.
 (Repeat slow down and rest during exercise.)
4. Measures for EIA
(i)  For children with asthma, who are prone to EIA, carefully observe them during exercise. If the signs of dyspnea appear, 
temporarily discontinue the exercise for abdominal breathing to recover from dyspnea.
Note) Explain EIA to other children beforehand to prevent them from misunderstanding.
(ii)  Patients with severe dyspnea incurable by abdominal breathing
 (e.g., (i) intensive retractive breathing, (ii) fragmentary speech, and (iii) cyanosis)
Use a preliminarily-prepared agent (e.g., inhaled β2 stimulant), or deliver to a medical institution.
5. If exercise is performed more intensively than routine exercise at school
Reportedly, some athletes, who participate in national athletic meetings, suffer from severe asthma during intensive training
or die from asthma if insufficiently controlled.
Thus, to perform exercise more intensively than usual, examine amount of exercise, training methods, and medications with 
attending physicians.
Food dependent exercise-induced anaphylaxis (FDEIAn):
Anaphylaxis, caused by both food intake and exercise, is called food dependent exercise-induced anaphylaxis (FDEIAn). Typically, fol-
lowing eruption of about 10-15 mm urticaria, FDEIAn causes respiratory symptoms, such as wheezing, laryngeal edema, and dyspnea and 
gastrointestinal symptom, such nausea and vomiting, and may progress to the collapse accompanied by unconsciousness.
Symptoms are generally induced by exercise ≤4 h after food intake. No anaphylaxis is induced by exercise >4 h after food intake. Com-
mon causative foods include wheat, squid, octopus, shellfi sh, shrimp, and crab. Others include fruits and nuts.
FDEIAn may be caused by increased histamine level due to mast cell degranulation. If cutaneous symptoms are noted during exercise, 
immediately discontinue the exercise, prescribe an antihistaminics, and consult a medical institution. Instruct patients to avoid causative
foods of FDEIAn. For emergency use, instruct them to carry antihistaminics and adrenaline for self-injection at any time (Epipen®).
(4) Puberty (junior high school students or older
children): More patients disobey their parents be-
cause of parent-child conflicts during puberty. Treat-
ment and management will be interrupted by delayed
education and instruction. This results in poor control
and increased risks of death from asthma. Directly in-
struct patients at consultation. Since enough time
cannot be taken in outpatient departments, it is effec-
tive to hospitalize patients with a severe persistent
asthma for education and instruction during summer
vacation, etc.
9. IMPROVEMENT IN COMPLIANCE
Sharing a treatment goal and establishing a partner-
ship are important. Repeatedly check basic knowl-
edge and skills at consultation to achieve a positive at-
titude toward treatment and high compliance.53
Points to improve compliance are shown in Table 27.
10. PRECAUTIONS FOR VACCINATION
Conditions such as bronchial asthma, atopic dermati-
tis, allergic rhinitis, urticaria, or allergic predisposi-
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Table　27　Points to improve compliance
- Recognize seriousness and urgency of asthma and death from it.
Asthma may cause death. Overuse of β2 stimulants, omission of long-term management agents, and emergency department 
visits only when seizures occur increase the risks of death from asthma.
- Patients should have prospects of cure through proper management.
Asthma remits if managed properly. Indicate a proper treatment method for patients to have prospects of asthma treatment.
- Develop self-efficacy, “I can.”
Confi dence in asthma management, “I can do this,” results in continued treatment. For that purpose, practical, specifi c, and 
less stressful instructions are required depending on their lives.
At every visit, praise the efforts and results of self-monitoring using asthma diary, prepared by patients or their families, to in-
crease their confi dence in treatment.
Table　28　Precautions for examining pubertal and adolescent asthma
1. Caution should be exercised for progress (regarding disease conditions).
- Reduced relations of respiratory function and airway hyperresponsiveness with symptoms
- Reduced involvement of atopy
- More common among women (seizures during the second half of menstrual period).
2. Complications (chest pain, dyspnea, headache, vomiting, etc.).
- Mediastinal and subcutaneous emphysema, pneumothorax, etc.
- Psychosomatic complications (hyperventilation syndrome, etc.)
- Intentional overdose, underdose, etc.
3. Management shift (patients’ acceptance of change from maternal to paternal management)
- Partnerships between hospitals and clinics, pediatric and internal departments, and hospitals and workplaces/schools.
4. Death from suffocation.
- Take cautions for patients living alone.
- Instructions for inhalation and medication
- Establishment of emergency system and staffing of personnel who takes charge of respiratory management on ambulances
5. Prevention of suffocation during puberty
- Appropriate early intervention
- Knowledge about environmental management (pet, tobacco, etc.)
- Partnership among hospitals, schools, and families
- Career and academic advices
6. Others
- Partnership with asthma (get along with asthma).
If poorly-controlled, reexamine the followings:
(i)  Compliance
(ii)  Periodic consultation
(iii)  Overuse of β2 blocker
(iv)  Indication of inhaled corticosteroids
Discuss these with patients.
tion alone do not preclude vaccination; however, cau-
tion should be exercised for patients potentially aller-
gic to vaccine components. Conduct a preliminary di-
agnosis considering previous allergic symptoms and
vaccine additives.
10.1. VACCINE ADDITIVES AND INOCULUM
COMPONENTS FOR ALLERGY
Reportedly, gelatin (stabilizer), thimerosal (antisep-
tics), egg ingredients (culture components), and an-
timicrobials can cause allergy. Of domestically-
produced vaccines, only the polio vaccine contains
gelatin (0.00375 mgdose). In inactivated vaccines,
thimerosal is removed or reduced to about 110 or
a substitute is used.
10.2. MAJOR VACCINES FOR CHILDREN WITH
ASTHMA
(1) Influenza vaccine: Influenza vaccines can be
safely used to inoculate children with 3.5 UAmL
egg white-specific IgE antibody titer (RAST score
3), who eat egg processed products, etc., without
serious adverse effects. Refer to a specialist for inocu-
lation of children (i) on an egg-free diet who are
known to have an egg allergy, (ii) with serious ana-
phylaxis after egg consumption, and (iii) with poorly
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controlled severe asthma.
(2) Mixed vaccine for measles and rubella: If im-
mediate hypersensitivity reaction (urticaria, etc.) oc-
curs immediately after the first inoculation with a
measles vaccine, measure measles antibody titer
(neutralizing or EIA-IgG antibody), and avoid a sec-
ond inoculation if antibody is found, or perform an in-
tradermal reaction test before the second inoculation
is given. Avoid reinoculation into patients with an im-
mediate anaphylactic reaction after the last inocula-
tion of a measles vaccine.
11. CONSIDERATIONS FOR SURGERY
Since asthma is a risk factor in performing general
anesthesia, especially inhalation anesthesia, caution
should be exercised for management of physical con-
ditions before and during surgery and for respiratory
management after surgery. For nonemergent surgery
in patients with aggressively introduced ICS, a period
exceeding 2 weeks of non-paroxysmal symptoms is
recommended. Even for nonemergent surgery, rela-
tively short-term asthma control is often demanded.
However, it takes several months to reduce airway
hyperresponsiveness sufficiently. Postpone surgery
until sufficient control is achieved. If asthma attack
occurs within 2 weeks, surgery should be postponed.
Complications and allergic reactions to medications,
medical materials, latex, foods, etc. must be investi-
gated prior to administration.
For patients receiving systemic steroid administra-
tion for severe asthma for6 months and those with
adrenocortical insufficiency, 2 mgkg prednisolone
should be started on the day before surgery, and con-
tinued even during surgery if possible. Systemic ster-
oid administration should be applied after surgery as
well.
12. PUBERTAL TO ADOLESCENT ASTHMA
Problems increase during puberty, e.g., low compli-
ance, remodeling, and death from asthma.54 Under-
standing the characteristics and problems of pubertal
asthma is important for treatment and management.
Precautions for patients, whose consultation is irregu-
lar and compliance with medication is low, are shown
in Table 28.
13. PATIENTS TO BE REFERRED TO A SPE-
CIALIST
If there is any problem with diagnosis or treatment,
determined by control status, or if complications are
found, refer the patient to a specialist for consultation.
Even if a patient is well-controlled, a non-specialist
and specialist should cooperate to assess the patient’s
condition objectively. Refer the following patients to a
specialist:
(1) Patients <2 years old
(i) Patients who require systemic steroid treatment
for 3 days a month or several times yearly. (ii) Pa-
tients who require treatment step 3 or above.
(2) Patients2 years old
(i) Patients who require systemic steroid treatment
frequently or continuously because of repeated sei-
zures. (ii) Patients who cannot be controlled by treat-
ment step 4.
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